The hematopathology of cefonicid- and cefazedone-induced blood dyscrasias in the dog.
Cephalosporin treatment in man has been associated with blood dyscrasias that include a time- and dose-related anemia, neutropenia, and thrombocytopenia, the hematopathology of which remains poorly characterized. A similar hematologic syndrome can be produced in dogs following daily intravenous injections of 540-840 mg/kg cefazedone or 400-500 mg/kg cefonicid for 1-3 months. Using this animal model, histologic and cytologic changes in blood, bone marrow, spleen, and liver were studied over the course of the cephalosporin-induced cytopenias. Peripheral blood cytologic observations included an absence, generally, of erythroid regenerative changes, increased numbers of macroplatelets, spherocytosis, erythroblastemia, and toxic neutrophil morphology. Interim and postmortem cytologic and histologic observations of bone marrow included hypoplastic and toxic changes, primarily in cytopenic dogs receiving high doses of cefonicid, and regenerative changes in hematopoietic tissue of affected cefazedone-treated animals. The latter included variable erythroid hyperplasia, increased megakaryocytes, and decreased marrow fat and was accompanied by evidence of extra-medullary hematopoiesis and increased hemosiderin and hemophagocytosis in liver and splenic tissue. The incidence and severity of these changes were dose-dependent, corresponded with the cytopenias observed peripherally, and, like the cytopenias, were fully reversible. These observations suggest that the hematologic syndrome associated with cephalosporin treatment in the dog has multiple toxicologic mechanisms, which include peripheral cytotoxic effects and bone marrow damage with depressed or ineffective hematopoiesis.
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D002435:Cefamandole / Q000031:analogs & derivatives* / Q000633:toxicity; D002437:Cefazolin / Q000031:analogs & derivatives* / Q000633:toxicity; D015790:Cefonicid; D002511:Cephalosporins / Q000633:toxicity*; D004195:Disease Models, Animal; D004285:Dogs; D006410:Hematopoiesis / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects; D010265:Paraproteinemias / Q000139:chemically induced*
D002511:Cephalosporins; D002435:Cefamandole; D015790:Cefonicid; C021341:cefazedone; D002437:Cefazolin